貝康醫療-B(02170.HK)中期業績：PGT-A試劑盒獲國家創新審批，引領胚胎智能化管理全球佈局
格隆匯8月29日丨貝康醫療-B(02170.HK)公佈中期業績，截至2025年6月30日止六個月，收入達到人民幣1.01億元，在遺傳檢測方面，集團的PGT–A試劑盒獲得了中國首個“國家創新醫療器械特別審批”三類醫療器械註冊證(國械注準20203400181)，並持續推進PGT領域的拓展，幫助臨牀實務實現更全面的優生優育解決方案。
在男科診斷方面，集團推出了BKA–210智能精子質量分析儀，可在三分鐘內完成無損、準確的活精子質量分析，並通過AI算法顯著提升檢測效率；BKP200便攜式精子質量分析儀則將專業級檢測拓展至家庭場景，推動普惠化應用。在冷凍存儲方面，集團的BCT38智能液氮罐是國內首個國家藥監局獲批並通過CE認證的產品，實現了樣本存儲的實時監控與安全管理；同時推出的SG800超低溫存儲系統，單機容量可達3~5萬管，並支持與病歷系統對接，實現零誤差、智能化的樣本保存。
在胚胎培養方面，集團通過收購新加坡BMX，獲得了國際領先的Geri®全時差胚胎培養箱與Gems®胚胎培養液，並於2025年7月取得江蘇藥監局就Geri®全時差培養箱頒發的二類醫療器械註冊證(蘇械注準20252181382)，標誌着這備受矚目的胚胎培養設備成功由進口轉爲國產。研究顯示，該培養體系可顯著提升胚胎質量和妊娠成功率，同時集團在國產化後進一步優化，顯著提升臨牀可及性。
在海外市場方面，公司已建立覆蓋多個國家和地區的銷售與服務網絡，產品獲得FDA、CE、TGA等多個權威機構認證，並與多家國際領先生殖機構及科研中心開展合作，推進智能化IVF診所和科研項目落地。這些舉措不僅提升了公司品牌影響力，也爲國產化產品的全球推廣奠定了基礎。依託“全產業鏈平臺+國際品牌影響力+ AI智慧化升級”的三大戰略，集團不僅在中國市場鞏固了技術與品牌領先地位，也正在將中國自主創新的解決方案推向全球，爲實現優生優育與國家人口戰略目標貢獻力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
